{"entity":{"id":"nct00248287","kind":"trial","name":"PhII ICb With/Without Erbitux in MBC Pts","aka":[],"tldr":"A phase 2 trial of Carboplatin and Cetuximab in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.","summary":"PhII ICb With/Without Erbitux in MBC Pts is a phase 2 interventional study registered as NCT00248287 by US Oncology Research, with 154 participants enrolled, started 2005-07-28 and due to reach its primary completion in 2025-12. Interventions recorded: Irinotecan + Carboplatin and irinotecan + Carboplatin + erbitux. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT00248287","url":"https://clinicaltrials.gov/study/NCT00248287"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","cetuximab"],"companies":["mckesson-us-oncology","bms","pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT00248287","phase":"2","setting":"Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer","sponsor":"US Oncology Research","enrolled":154,"outcomes":[]},"route":"/trials/nct00248287/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}